Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)
Details for Australian Patent Application No. 2002340183 (hide)
International Classifications
Event Publications
27 February 2003 Complete Application Filed
Priority application(s): 60/328,806 15.10.01 US
3 July 2003 Application Open to Public Inspection
Published as AU-B-2002340183
30 October 2008 Alteration of Name
The name of the applicant has been altered to Novartis Vaccines and Diagnostics, Inc. 2003
13 November 2008 Application Accepted
Published as AU-B-2002340183
12 March 2009 Standard Patent Sealed
12 May 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired
This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2002340184-Imidazo (4,3-E)-1,2,4-triazolo(1,5-C) pyrimidines as adenosine A2A receptor antagonists
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser